drugset / Trial / NCT01015391

Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease

NCT01015391

Unknown 100 enrolled Jinling Hospital, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to see whether T2 versus Azathioprine is able to maintain the clinical and endoscopic remission in subjects with Crohn's disease after surgery-induced remission. The side effects related to T2 and AZA will also be monitored throughout the study.

Timeline

Start
2009-11
Primary completion
2013-06
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 2.5 mg/kg Oral
Subject T2 [arm: experimental] — 1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops Traditional medicine (herbal / TCM) 1.5 mg/kg Oral

Indications